89bio Inc Stock Today
| ETNB Stock | USD 9.64 0.91 10.42% |
Performance3 of 100
| Odds Of DistressLess than 9
|
89bio is trading at 9.64 as of the 30th of January 2025, a 10.42 percent increase since the beginning of the trading day. The stock's open price was 8.73. 89bio has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of November 2019 | Category Healthcare | Classification Health Care |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. The company has 117.58 M outstanding shares of which 8.35 M shares are currently shorted by private and institutional investors with about 6.81 trading days to cover. More on 89bio Inc
Moving against 89bio Stock
| 0.43 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
89bio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt Levels89bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 89bio's financial leverage. It provides some insight into what part of 89bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
89bio Inc (ETNB) is traded on NASDAQ Exchange in USA. It is located in 142 Sansome Street, San Francisco, CA, United States, 94104 and employs 70 people. 89bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.03 B. 89bio Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 117.58 M outstanding shares of which 8.35 M shares are currently shorted by private and institutional investors with about 6.81 trading days to cover.
89bio Inc currently holds about 193.34 M in cash with (129.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.16.
Check 89bio Probability Of Bankruptcy
Ownership Allocation89bio holds a total of 117.58 Million outstanding shares. The majority of 89bio Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 89bio Inc to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in 89bio. Please pay attention to any change in the institutional holdings of 89bio Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check 89bio Ownership Details
89bio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 2.6 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.1 M | |
| Redmile Group, Llc | 2024-09-30 | 1.6 M | |
| Adage Capital Partners Gp Llc | 2024-09-30 | 875 K | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 871.4 K | |
| Candriam Luxembourg S.c.a. | 2024-09-30 | 848.1 K | |
| Laurion Capital Management Lp | 2024-09-30 | 810.5 K | |
| Alyeska Investment Group, L.p. | 2024-09-30 | 808.6 K | |
| Northern Trust Corp | 2024-09-30 | 794.7 K | |
| Hhg Plc | 2024-09-30 | 15.2 M | |
| Ra Capital Management, Llc | 2024-09-30 | 14.2 M |
89bio Historical Income Statement
89bio Stock Against Markets
89bio Corporate Management
| Harry MD | Chief Officer | Profile | |
| Francis Sarena | Chief Officer | Profile | |
| Rohan Palekar | CEO Director | Profile | |
| Quoc LeNguyen | Chief Quality | Profile | |
| Shiva CPA | Senior Officer | Profile | |
| Shiva Natarajan | Senior Officer | Profile | |
| Amanda Hill | VP Culture | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 89bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.